SLC5A2 and chronic kidney disease: In patients with diabetic nephropathy and significant albuminuria, the use of renin-angiotensin system (RAS) inhibitors [1,3], sodium-glucose cotransporter-2 inhibitors (SGLT2i) [1,4], and the non-steroidal mineralocorticoid receptor antagonist finerenone [1,5] has been shown to slow the progression to end-stage renal disease.